Molecular Targeted Cancer Therapies More drugs on the market more targets in the pipeline

Introduction

Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Scope of this report

Seven major pharmaceutical market sales forecasts from 2005 to 2015 for approved molecular targeted therapies and key pipeline candidates

Review of the current targeted therapies market, including profiles, product-specific assumptions and events over the forecasted period

Research and analysis of the targeted therapies pipeline with in-depth clinical and commercial assessment of Phase III candidates, plus expert opinion

Examination of product pipeline by phase, mode of action, indication, drug class and developer, plus two commercial impact case studies

Research and analysis highlights

In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9%. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and Avastin as well as Novartis' Gleevec, all of which have already reached blockbuster status.

274 different pipeline MTTs have been identified. The introduction of current late-phase candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the market's total value by $3.8 billion, enabling the targeted therapies market to reach $29.1 billion in 2015.

The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic pressures challenging healthcare payers globally. To counter these hurdles, developers must become more effective at communicating the value of their products. To this end, a comprehensive understanding of the targeted therapies market and pipeline is critical.

Key reasons to read this report

Acquire a detailed appreciation and impartial perspective of the targeted cancer therapies market as a whole

Consider and react to the specific events influencing the future potential of marketed and pipeline targeted therapies

Gain an insight into the emerging clinical, developmental and commercial challenges and opportunities facing key developmental and marketed MTT drugs

Published: 10 October 2006

Format: PDF
Table of Contents
Price: $15,200.00 / GBP8,360.00